SCHEMBL7066230

SCHEMBL7066230

NC(=O)c1ncn([C@@H]2O[C@H](CO)[C@@H](OCc3ccccc3)[C@H]2OCc2ccccc2)n1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.57
▸ SMN1; SMN2 Q16637 2/20 0.57
▸ ADORA1 P30542 2/20 0.57
▸ ALDH1A1 P00352 1/20 0.57
▸ GLA P06280 1/20 0.57
▸ EIF4E P06730 1/20 0.57
▸ CYP3A4 P08684 1/20 0.57
▸ TOP1 P11387 1/20 0.57
▸ TSHR P16473 1/20 0.57
▸ THPO P40225 1/20 0.57
▸ PMP22 Q01453 1/20 0.57
▸ PNP P00491 2/20 0.44
▸ HTR1A P08908 1/20 0.40
▸ TACR2 P21452 1/20 0.39
▸ BCHE P06276 1/20 0.39
▸ ADORA2A P29274 1/20 0.38
▸ ADORA2B P29275 1/20 0.38
▸ CYP1A2 P05177 1/20 0.37
▸ SLC29A1 Q99808 1/20 0.37
▸ PTPN2 P17706 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11654958 0.90 HTR1A (0.52) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL6912924 0.81 LMNA (0.57) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL6130809 0.78 LMNA (0.45) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL12150476 0.77 LMNA (0.54) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL14546644 0.75 LMNA (0.74) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL15031296 0.75 LMNA (0.74) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL13873177 0.74 LMNA (0.60) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL6839414 0.74 LMNA (0.60) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL13713970 0.74 LMNA (0.60) LMNASMN1; SMN2ADORA1ALDH1A1GLA
SCHEMBL13714018 0.74 LMNA (0.60) LMNASMN1; SMN2ADORA1ALDH1A1GLA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040023901-A1 Nucleoside 5'-monophosphate mimics and their prodrugs BIOTA HOLDINGS LIMITED (AU) 2004-02-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023901-A1 Nucleoside 5'-monophosphate mimics and their prodrugs MTAP, ENTPD5, PNP LMNA 4394/4885SMN1; SMN2 2624/4885ADORA1 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback